僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類或動物的臨床診斷或治療，非藥用. Flotetuzumab （MGD006; S80880） is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody （DART） molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft （PDX） in acute myeloid leukemia （AML）